<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193319</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-I-108</org_study_id>
    <nct_id>NCT04193319</nct_id>
  </id_info>
  <brief_title>Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects</brief_title>
  <official_title>Study on the Pharmacokinetics of Fluconazole on Single-center, One-arm, Open and Fixed Sequences of Fluzoparib in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Effect of fluconazole on the Pharmacokinetics of&#xD;
      Fluzoparib in Healthy male Adults&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects received oral Fluzoparib 20 mg after D1 single meal, D2-D4 for washing period, D5&#xD;
      started oral fluconazole 400 mg/day/day after meal, continuous administration for 6 days to&#xD;
      D10, D8 meal After oral administration of fluconazole 400 mg, a single oral dose of&#xD;
      Fluzoparib 20 mg was given immediately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration(Cmax) of Fluzoparib</measure>
    <time_frame>through study completion，up to 24 weeks</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma Concentration-time curve From 0-t of Fluzoparib</measure>
    <time_frame>through study completion，up to 24 weeks</time_frame>
    <description>AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma Concentration-time curve From 0 to infinity of Fluzoparib</measure>
    <time_frame>through study completion，up to 24 weeks</time_frame>
    <description>AUC0-∞</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety in terms of Adverse Events Assessments</measure>
    <time_frame>through study completion，up to 24 weeks</time_frame>
    <description>NCI-CTC AE 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>PARP inhibitor</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>inhibitor</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 35- 50 years old (including both ends), male;&#xD;
&#xD;
          2. The body weight is not less than 50 kg, and the body mass index [BMI = weight kg /&#xD;
             (height m) 2] is in the range of 18 to 28 (including the critical value);&#xD;
&#xD;
          3. Subjects are willing to have no birth plans in the next 6 months and voluntarily take&#xD;
             effective contraceptive measures;&#xD;
&#xD;
          4. Good health, no history of heart, liver, kidney, digestive tract, nervous system and&#xD;
             metabolic abnormalities;&#xD;
&#xD;
          5. There are no abnormalities or abnormalities in vital signs and physical examination.&#xD;
&#xD;
          6. Understand the research procedures and methods, voluntarily participate in the trial,&#xD;
             and sign the informed consent in writing. Fully understand the test content, process&#xD;
             and possible adverse reactions;&#xD;
&#xD;
          7. Creatinine is less than or equal to the upper limit of normal;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participate in blood donation within 3 months before screening and donate blood volume&#xD;
             ≥400mL or blood loss ≥400mL, participate in blood donation within one month and donate&#xD;
             blood volume ≥200mL or blood loss ≥200mL, or receive blood transfusion;&#xD;
&#xD;
          2. Allergies, including a history of severe drug allergies or drug allergies; a history&#xD;
             of allergies to fluzolidine capsules or their excipients.&#xD;
&#xD;
          3. Those who have a history of drug and/or alcohol abuse, who are positive for alcohol&#xD;
             and drug screening, or who have used drug abuse in the past five years or who have&#xD;
             used drugs three months before the test;&#xD;
&#xD;
          4. People who smoke alcohol (drinking 14 units of alcohol per week: 1 unit = beer 285 mL,&#xD;
             or spirits 25 mL, or wine 100 mL; daily smoking ≥ 5) and can not be smoke-free and&#xD;
             alcohol-free during the test period ;&#xD;
&#xD;
          5. Those with previous history of cardiovascular disease such as cardiac insufficiency,&#xD;
             myocarditis, coronary heart disease, pathological arrhythmia, and stroke;&#xD;
&#xD;
          6. Pulmonary diseases, including invasive lung disease, pneumonia, difficulty breathing,&#xD;
             etc.;&#xD;
&#xD;
          7. History of chronic kidney disease, renal insufficiency, and renal anemia;&#xD;
&#xD;
          8. Have a history of dysphagia or any history of gastrointestinal disease that affects&#xD;
             drug absorption;&#xD;
&#xD;
          9. Any uncontrolled peptic ulcer, inflammatory bowel disease, pancreatitis, etc.;&#xD;
&#xD;
         10. Anyone who has undergone any surgery within the first 6 months of screening; has&#xD;
             undergone any surgery that affects gastrointestinal absorption (including gastrectomy,&#xD;
             bowel resection, stomach reduction, etc.)&#xD;
&#xD;
         11. A clear history of other major organ diseases such as the nervous system,&#xD;
             cardiovascular system, urinary system, digestive system, respiratory system,&#xD;
             metabolism and musculoskeletal system within the first month prior to screening (eg&#xD;
             uncontrolled diabetes, hypertension) Etc.), making the researcher feel unsuitable for&#xD;
             participation in the study;&#xD;
&#xD;
         12. Hepatotoxic drugs (such as acetaminophen, statin lipid-lowering drugs, azithromycin,&#xD;
             dapsone, clarithromycin, fluconazole, ketoconazole, etc. within 6 months prior to&#xD;
             screening (for more than 2 consecutive weeks) Li Fuping);&#xD;
&#xD;
         13. Those who have taken any clinical trial drug within 3 months;&#xD;
&#xD;
         14. Take any medication that alters liver enzyme activity 28 days prior to taking the&#xD;
             study drug (see Appendix 1);&#xD;
&#xD;
         15. Take any prescription or over-the-counter medication 14 days before taking the study&#xD;
             drug;&#xD;
&#xD;
         16. Ingested any vitamin products or herbs 14 days prior to taking the study drug;&#xD;
&#xD;
         17. Clinical laboratory tests are abnormal and clinically significant, or other clinical&#xD;
             findings indicate the following diseases (including but not limited to&#xD;
             gastrointestinal, renal, hepatic, neurological, blood, endocrine, tumor, lung, immune,&#xD;
             mental or cardiovascular) disease);&#xD;
&#xD;
         18. Concomitant infection with other viruses (anti-HCV, anti-HIV positive, HBsAg positive)&#xD;
             or syphilis infection;&#xD;
&#xD;
         19. Ingested grapefruit or grapefruit-containing products, caffeine, jaundice or alcoholic&#xD;
             foods or beverages (including chocolate, tea, coffee, cola, etc.) 48 hours prior to&#xD;
             taking the study drug; strenuous exercise, or other Factors affecting drug absorption,&#xD;
             distribution, metabolism, excretion, etc.;&#xD;
&#xD;
         20. According to the chest X-ray and abdominal B-ultrasound examination items at the time&#xD;
             of screening, abnormalities and clinical significance were confirmed.&#xD;
&#xD;
         21. The investigator believes that there are other subjects who are not eligible to&#xD;
             participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Early Cancer Research Center of Hunan Cancer Hospital</name>
      <address>
        <city>Hunan</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>December 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 8, 2019</last_update_submitted>
  <last_update_submitted_qc>December 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

